HFpEF精准医疗时代到来了吗?

详细信息

收稿日期: 2019-02-01

Is the era of precision medicine in heart failure coming?

- Department of Cardiology, Union Hospital, Huazhong University of Science and Technology, 430022, China

More Information

Received Date: 01 February 2019

摘要: 心力衰竭（心衰）是一种异质性临床综合征，精准医疗可以将心衰进一步细分成不同的亚类，将具有共同病理生理机制的归为一类，以寻求更为精确的靶点治疗。针对射血分数保留的心衰（HFpEF），其临床表型特异，治疗和临床研究需要个体化和针对性，摒弃“一双鞋子套所有脚”的思维模式。本文将探讨目前精准医疗在HFpEF中应用的可行性。
- 心力衰竭 /
- 射血分数保留 /
- 精准医疗
Abstract: Heart failure (HF) is a heterogeneous clinical syndrome.The precision medicine tries to classify HF into subgroups that have more homogeneous disease pathophysiology and may respond in a more consistent manner to specific treatments, especially for HFpEF.The clinical management of HFpEF patients and future HFpEF clinical trials will both likely require a nuanced, phenotype-specific approach instead of a one-size-fits-all tactic.Here, we provide an overview of precision medicine in HFpEF.
- heart failure /
- preserved ejection fraction /
- precision medicine

[1]	Shah SJ.Targeted therapeutics for transthyretin cardiac amyloidosis[J].Circulation, 2019, 139(4):444-447.
[2]	Shah SJ.Precision medicine for heart failure with preserved ejection fraction:an overview[J].J Cardiovasc Transl Res, 2017, 10(3):233-244.
[3]	MacRae CA, Seidman CE.Closing the genotype-phenotype loop for precision medicine[J].Circulation, 2017, 136(16):1492-1494.
[4]	Maurer MS, Schwartz JH, Gundapaneni B, et al.ATTR-ACT Study Investigators.Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy[J].N Engl J Med, 2018, 379(11):1007-1016.
[5]	Adams D, Gonzalez-Duarte A, O'Riordan WD, et al.Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis[J].N Engl J Med, 2018, 379(1):11-21.
[6]	Everett BM, Cornel JH, Lainscak M, et al.Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure[J].Circulation, 2018, doi:10.1161/CIRCULATIONAHA.118.038010.
[7]	Shah, SJ.Innovative clinical trial designs for precision medicine in heart failure with preserved ejection fraction[J].J Cardiovasc Transl Res, 2017, 10(3):322-336.
[8]	Santema BT, Kloosterman M, Gelder V.et al.Comparing biomarker profile of patients with heart failure:atrial fibrillation vs sinus rhythm and reduced vs preserved ejection fraction[J].Eur Heart J, 2018, 39(43):3867-3875.